TUSTIN, CA--(Marketwire - July 22, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it will present at the 2010 American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo to be held at the Anaheim Convention Center July 25-29.
The American Association for Clinical Chemistry (AACC) is an international society of clinical laboratory professionals, physicians, research scientists and others who are involved in clinical chemistry and clinical laboratory science. The annual AACC meeting is the world's largest gathering of clinical lab professionals dedicated to improving laboratory science and healthcare in all facets. Its nearly 10,000 members include clinical lab directors, physicians, research scientists, and healthcare industry professionals. This prestigious event provides Radient Pharmaceuticals the valuable opportunity to meet with conference attendees and showcase the Company's US FDA-approved Onko-Sure™ in vitro diagnostic (IVD) cancer test. The Company will also provide attendees with the latest clinical studies and product information on Onko-Sure.
With more than 1,800 booths and 650 exhibitors, AACC features more than 250 educational sessions examining the latest information on a wide range of clinical laboratory testing developments, including aging, cancer, chronic disease management, diabetes, global health issues, and infectious diseases. A complete list of topics being covered at the event is available at http://direct.aacc.org/am/AMBrowse.aspx?Dim=edtopics. The annual meeting features the AACC Clinical Lab Expo -- the largest gathering of laboratory industry companies in the world. Attendees from across the world get to see first-hand the latest developments and advances in laboratory science.
"We are excited to present our Onko-Sure IVD cancer test at this critically important industry event," stated Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. "AACC is the premier stage for the latest in innovative lab science and new technologies related to clinical diagnostics and testing. Our goal is to use this event as a forum to highlight the benefits of Onko-Sure as a potentially life-saving cancer test for at risk patients and populations worldwide." RPC's Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test. For more information visit www.onko-sure.com.
RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko-Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical's current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Radient Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel) 206.310.5323
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati:
